Jonathan Schwartz
Net Worth

Last updated:

What is Jonathan Schwartz net worth?

The estimated net worth of Mr. Jonathan Schwartz is at least $5,015,138 as of 17 Feb 2023. He owns shares worth $280,802 as insider, has earned $2,255,536 from insider trading and has received compensation worth at least $2,478,800 in Rocket Pharmaceuticals, Inc..

What is the salary of Jonathan Schwartz?

Mr. Jonathan Schwartz salary is $619,700 per year as Chief Medical Officer & Senior Vice President of Clinical Devel. in Rocket Pharmaceuticals, Inc..

How old is Jonathan Schwartz?

Mr. Jonathan Schwartz is 61 years old, born in 1964.

What stocks does Jonathan Schwartz currently own?

As insider, Mr. Jonathan Schwartz owns shares in one company:

Company Title Shares Price per share Total value
Rocket Pharmaceuticals, Inc. (RCKT) Chief Medical Officer & Senior Vice President of Clinical Devel. 94,546 $2.97 $280,802

What does Rocket Pharmaceuticals, Inc. do?

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT), Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; CIEMAT and UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. is headquartered in Cranbury, New Jersey.

RCKT logo
RCKT
Rocket Pharmaceuticals, Inc.
$2.97

Jonathan Schwartz insider trading

Rocket Pharmaceuticals, Inc.

Mr. Jonathan Schwartz has made 7 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 3,557 units of RCKT stock worth $67,796 on 17 Feb 2023.

The largest trade he's ever made was exercising 224,529 units of RCKT stock on 1 Feb 2021. As of 17 Feb 2023 he still owns at least 94,546 units of RCKT stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 3,557 $19.06 $67,796
Option
Common Stock 8,574 N/A N/A
Option
Restricted Stock Units 8,574 N/A N/A
Sale
Common Stock 12,974 $15.86 $205,768
Sale
Common Stock 32,026 $16.2 $518,821
Sale
Common Stock 35,998 $16.15 $581,368
Sale
Common Stock 9,002 $15.9 $143,132
Sale
Common Stock 34,438 $16.56 $570,293
Sale
Common Stock 10,562 $15.94 $168,358
Option
Common Stock 224,529 $1.45 $325,567

Rocket Pharmaceuticals key executives

Rocket Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:

  • Dr. Gaurav D. Shah (50) Chief Executive Officer & Director
  • Mr. John C. Militello CPA, CPA (52) Vice President, Senior Controller & Principal Accounting Officer
  • Mr. Jonathan Schwartz (61) Chief Medical Officer & Senior Vice President of Clinical Devel.
  • Ms. Kinnari Patel M.B.A., Pharm.D., PharmD, MBA (46) Pres, Chief Operating Officer & Head of Devel.